Oddo BHF - BioNTech SE (BNTX) BioNTech SE : Launch of an independent mRNA company by the founders

Report

Oddo BHF

Martial Descoutures

BioNTech SE : Launch of an independent mRNA company by the founders

11/03/2026 1 EN

Underlying

BioNTech SE

See profile

US09075V1026 NASDAQ Stock Market Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Martial Descoutures

Other Reports on these Companies

GlobeNewsWire

BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren, Antikörper-Wirkstoff-Konjugate und mRNA-Krebsimmuntherapien sowie deren Kombinationen umfasstDaten-Updates zu Pumitamig aus drei klinischen Studien in China unterstreichen das bereits beobachtete Wirksamkeits- und Sicherheitsprofil des bispezifisc...

March 24, 2026 March 24, 2026 1 EN

GlobeNewsWire

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer immunotherapies, and their combinationsData updates for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator, from three clinical trials conducted in China further strengthen the evidence supporting its previously observed efficacy and safety profile in lung cancerResults of...

March 24, 2026 March 24, 2026 1 EN

Oddo BHF

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 03/11/2026

March 11, 2026 March 11, 2026 1 EN

Ipsen : Q1 2026 revenue preview: solid growth and in line with guidance

4m 4m 1 EN

Pierre François Merveille

Pierre François Merveille

Fibercop (Optics) : Buy recommendation on FIBCOP notes

4m 4m 1 EN

Christophe-Raphaël Ganet

Christophe-Raphaël Ganet

Ipsen : Preview CA T1 2026: croissance solide et conforme à la guidance

4m 4m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BioNTech SE : Launch of an independent mRNA company by the founders

BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

ODDO BHF SECURITIES LARGE CAPS MORNING NEWS 03/11/2026

Ipsen : Q1 2026 revenue preview: solid growth and in line with guidance

Fibercop (Optics) : Buy recommendation on FIBCOP notes

Ipsen : Preview CA T1 2026: croissance solide et conforme à la guidance

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe